Increased prevalence of TH17 cells in the peripheral blood of patients with head and neck squamous cell carcinoma

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 112, Issue 1, 2011, Pages 81-89

  Li, Chen ^a   Zhao, Yifang ^a   Zhang, Wenfeng ^a   Zhang, Wei ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MALE; METASTASIS; MIDDLE AGED; MOUTH MUCOSA; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TH17 CELL; TONGUE TUMOR;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; LYMPHATIC METASTASIS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM STAGING; TH17 CELLS; TONGUE NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 79958769959     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2010.11.032     Document Type: Article

References (28)

1. Bacchiocchi R, Rubini C, Pierpaoli E, Borghetti G, Procacci P, Nocini PF, et al. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study. BMC Cancer 2008;8:220.
2. Osaki T, Yoneda K, Yamamoto T, Kimura T, Matuoka H, Sakai H, et al. Clinical investigation on pulmonary metastasis of head and neck carcinomas. Oncology 2000;59:196-203.
3. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32. (Pubitemid 41541790)
4. H17 function in autoimmune inflammation. J Exp Med 2007;204:161-70.
5. H17 cells in autoimmunity. J Immunol 2007;178:1341-8.
6. H17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008;205:1551-7.
7. H17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008;181:4089-97.
8. H17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007;110:3804-13.
9. H17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007;178:6730-3.
10. H17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008;374:533-7.
11. H17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 2010;185:4063-71.
12. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007;104:3967-72. (Pubitemid 47181562)
13. Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005;65:3937-41. (Pubitemid 40616376)
14. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 1999;96:8633-8. (Pubitemid 29354843)
15. + T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol 2003;170:400-12.
16. H17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010;62:143-9.
17. H17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159:1092-102.
18. H17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008;205:3133-44.
19. H17-polarized cells eradicate large established melanoma. Blood 2008;112:362-73.
20. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009;31:787-98.
21. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-7. (Pubitemid 36857622)
22. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, et al. Interleukin 17, a T-cell- derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999;59:3698-704. (Pubitemid 29381875)
23. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell- dependent mechanism. Blood 2002;99: 2114-21. (Pubitemid 34525496)
24. H17 and regulatory T cells. l. Nature 2006;441:235-8.
25. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9. (Pubitemid 47300008)
26. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008;454:350-2.
27. H1 cells. Eur J Immunol 2009;39:207-15.
28. Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 2009;158:199-204.